Current Research: Medical Oncology

S0502-- Imatinib with or without Bevacizumab for Metastatic or Unresectable Gastrointestinal Stromal Tumors (GIST)

The purpose of this study is to find out whether the combination of imatinib and bevacizumab is better than the usual treatment of imatinib alone. We currently do not know if imatinib plus bevacizumab is better than imatinib by itself.

Imatinib is the usual treatment for GIST. Bevacizumab is an experimental drug. Although it has been approved by the FDA (Food and Drug Administration) for other types of cancer, it has not been approved for GIST.

Eligibility

You may be eligible for this trial if:

• You have a biopsy proven gastrointestinal stromal tumor (GIST) that is distantly metastatic or unresectable.
• You have measurable and/or non-measurable disease.
• You HAVE NOT HAD prior therapy with imatinib, bevacizumab, or other agents targeting KIT, VEGF, VEGFR, or PDGFR for advanced disease. Those agents may have been used in the adjuvant setting if you did not recur for at least 12 months.
• You may have had previous chemotherapeutic agents, provided at least 28 days have elapsed since completing chemotherapy and you have recovered from all drug-induced toxicities
• You may have had prior radiotherapy, provided at least 28 days have elapsed since the last treatment and there is no evidence of progressive disease.

Trial Sponsor

• Southwest Oncology Group (SWOG)

Project Begin Date

• Awaiting IRB Approval

Tentative Project End Date

• Jul 2012

Back to Medical Oncology Research

Revised March 30, 2009.   Please send comments, suggestions or questions about this page to Goldei Posey, gposey@mcg.edu .